

From: [Fishman, Deborah](#)
To: [Hawthorne, Eric W.](#); lgreen@geminilaw.com; raynimrod@quinnemanuel.com; [Trials](#)
Cc: ychu@wsgr.com; [Caine, David A.](#); Denuyl, David; Ho, Alice; matthewtraupman@quinnemanuel.com; landonsmith@quinnemanuel.com
Subject: RE: IPR20223-00532, -00533, and -00566 (note corrected number)
Date: Wednesday, March 1, 2023 9:41:36 PM
Attachments: [image001.png](#)

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Dear Eric,

Thank you for your inquiry. Patent Owner intends to waive POPR in IPR2023-00532 and IPR2023-00533 filed by Petitioner Celltrion, Inc.

However, in IPR2023-00566, filed by Samsung Bioepis, Patent Owner is still considering what it will do and is scheduled to meet and confer with counsel for Samsung Bioepis later this week. Once Patent Owner makes a decision, it will advise the Board promptly.

With best regards,
Deborah

Deborah Fishman
Partner | [Bio](#)

Arnold & Porter

3000 El Camino Real | Suite 500

Palo Alto, CA 94306-2112

T: +1 650.319.4773 | F: +1 650.319.4973

Deborah.Fishman@arnoldporter.com

www.arnoldporter.com | [LinkedIn](#) | [Twitter](#)

From: Hawthorne, Eric W. <Eric.Hawthorne@USPTO.GOV>

Sent: Wednesday, March 1, 2023 8:53 AM

To: Fishman, Deborah <Deborah.Fishman@arnoldporter.com>; lgreen@geminilaw.com; raynimrod@quinnemanuel.com; [Trials](#) <Trials@USPTO.GOV>

Cc: ychu@wsgr.com; [Caine, David A.](#) <David.Caine@arnoldporter.com>; Denuyl, David <David.Denuyl@arnoldporter.com>; Ho, Alice <Alice.Ho@arnoldporter.com>; matthewtraupman@quinnemanuel.com; landonsmith@quinnemanuel.com

Subject: IPR20223-00532, -00533, and -00556

External E-mail

Counsel, the Board is inquiring as to whether Patent Owner Regeneron Pharmaceuticals Inc. intends to file a Preliminary Response to the Petitions in these IPRs, or if it is Patent's Owner's intention is to

IPR2023-00532,
-00533 Ex. 3001

waive filings.

Thank you,
Eric W. Hawthorne

Supervisory Paralegal Specialist
Patent Trial and Appeal Board

This communication may contain information that is legally privileged, confidential or exempt from disclosure. If you are not the intended recipient, please note that any dissemination, distribution, or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

For more information about Arnold & Porter, click here:
<http://www.arnoldporter.com>